Asterias Biotherapeutics, Inc. (AST) Analysts See $-0.08 EPS on March, 21

Asterias Biotherapeutics, Inc. (NYSEAMERICAN:AST) Corporate Logo

On March, 21 is anticipated Asterias Biotherapeutics, Inc. (NYSEAMERICAN:AST)’s earnings report, according to Faxor. Analysts expect change of 33.33 % or $0.04 from previous year’s $-0.12 earnings per share compared to current’s $-0.08 earnings per share. Wall Street sees 0.00 % EPS growth as of March, 21. The stock decreased 8.41% or $0.0799 during the last trading session, touching $0.8701.Asterias Biotherapeutics, Inc. has volume of 141,010 shares. Since March 4, 2018 AST has declined 56.10% and is downtrending. AST underperformed by 56.10% the S&P 500.

Asterias Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapies in the fields of cell therapy and regenerative medicine.The company has $48.43 million market cap. The firm develops therapeutic products in the areas of neurology and oncology.Last it reported negative earnings. The Company’s clinical stage programs include AST-OPC1, a therapy derived from pluripotent stem cells that has completed a Phase I clinical trial for the treatment of thoracic spinal cord injuries; and that is in Phase I/IIa clinical trial for treating cervical spinal cord injuries, as well as for the treatment of multiple sclerosis and white matter stroke.

Asterias Biotherapeutics, Inc. (NYSEAMERICAN:AST) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.